Harmony Biosciences Holdings, Inc. (HRMY) is a Biotechnology company in the Healthcare sector, currently trading at $29.29. It has a SharesGrow Score of 82/100, indicating a strong investment profile with 5 out of 7 criteria passed.
SharesGrow calculates the intrinsic value of HRMY = $82.41 (+181.4% from the current price, the stock appears undervalued). Analyst consensus target is HRMY = $47 (+59.8% upside).
Valuation: HRMY trades at a trailing Price-to-Earnings (P/E) of 10.2 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 0.54.
Financials: revenue is $868M, +25.7%/yr average growth. Net income is $159M, growing at -2.3%/yr. Net profit margin is 18.3% (healthy). Gross margin is 77.2% (-3.7 pp trend).
Balance sheet: total debt is $240M against $870M equity (Debt-to-Equity (D/E) ratio 0.28, conservative). Current ratio is 3.6 (strong liquidity). Debt-to-assets is 18.8%. Total assets: $1.3B.
Analyst outlook: 10 / 13 analysts rate HRMY as buy (77%) — strong consensus.
SharesGrow 7-Criteria breakdown: Value 100/100 (Pass), Growth 58/100 (Partial), Past 100/100 (Pass), Health 100/100 (Pass), Moat 61/100 (Partial), Future 85/100 (Pass), Income 70/100 (Pass).
